Advertisement

Ads Placeholder
Loading...

TransCode Therapeutics, Inc.

RNAZ•NASDAQ
Healthcare
Biotechnology
$8.60
$-0.09(-1.04%)
U.S. Market opens in 21h 55m

TransCode Therapeutics, Inc. (RNAZ) Stock Overview

Explore TransCode Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

Z

Key Financials

Market Cap7.9M
P/E Ratio-0.26
EPS (TTM)$-236.52
ROE-6.85%
Fundamental Analysis

AI Price Forecasts

1 Month$3.63
3 Months$18.03
1 Year Target$0.00

RNAZ Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of TransCode Therapeutics, Inc. (RNAZ) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 41.04, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $0.00.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -0.26 and a market capitalization of 7.9M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

1-Day Change
-1.04%
5-Day Change
-3.04%
1-Month Change
-16.10%
3-Month Change
16.22%
6-Month Change
-18.64%
Year-to-Date (YTD) Change
16.22%
1-Year Change
-33.54%
3-Year Change
-100.00%
5-Year Change
-100.00%
All-Time (Max) Change
-100.00%

Contact Information

https://www.transcodetherapeutics.com
857-837-3099
6 Liberty Square, Boston, MA, 02109

Company Facts

70 Employees
IPO DateJul 8, 2021
CountryUS
Actively Trading

Frequently Asked Questions